AstraZeneca nabs FDA nod to challenge GSK's Benlysta with first-in-class lupus drug Saphnelo

After a 10-year drought in new treatments for systemic lupus, the FDA has waved through a new drug.

The FDA cleared AstraZeneca’s Saphnelo (anifrolumab) to treat moderate to severe systemic lupus erythematosus (SLE), the most common form of lupus, the company said Monday.